Search Results for "f"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for f. Results 261 to 270 of 864 total matches.
Minimal Surgery for Treatment of GERD
The Medical Letter on Drugs and Therapeutics • Sep 01, 2003 (Issue 1164)
., Vanderbilt School of Medicine; F. Estelle R. Simons, M.D., University of Manitoba EDITORIAL FELLOWS ...
Laparoscopic surgery has become increasingly popular for the treatment of gastroesophageal reflux disease (GERD). The usual surgical procedure, a Nissen fundoplication, prevents reflux into the esophagus. The review compares medical treatment with a proton pump inhibitor vs. surgical therapy as well as open vs. the new laparoscopic technique. Morbidity and mortality with the procedures are discussed.
Do NSAIDs Interfere with the Cardioprotective Effects of Aspirin?
The Medical Letter on Drugs and Therapeutics • Aug 02, 2004 (Issue 1188)
with the antiplatelet effect of aspirin (F Catella-Lawson
et al, N Engl J Med 2001; 345:1809). Celecoxib (Celebrex ...
Low-dose aspirin is widely used as an antiplatelet drug to reduce the risk of cardiovascular disease (Medical Letter 2000; 42:18). Recent reports suggest that the nonsteroidal anti-inflammatory drug (NSAID) ibuprofen (Motrin, and others) may decrease the efficacy of aspirin for this indication. The manufacturer of Tylenol is capitalizing on these reports by advertising that aspirin-taking patients who need pain relief should use acetaminophen instead of ibuprofen.
Addendum: Dermal Fillers
The Medical Letter on Drugs and Therapeutics • Jul 16, 2007 (Issue 1265)
., University Hospital, Copenhagen
Dan M. Roden, M.D., Vanderbilt University School of Medicine
F. Estelle R ...
Some Medical Letter consultants have suggested that our recent article on dermal fillers (Med Lett Drugs Ther 2007; 49:39) should have included stronger warnings about the risk of fillers that are not biodegradable, such as Artefill. The polymethylmethacrylate (PMMA, the same material that makes up Plexiglas) beads in Artefill can over time, even with the best technique, cause foreignbody granulomas and hypertrophic scarring, which may require surgical removal. Granulomas and nodules have been especially frequent when Artefill was injected into the lips. Complications are less likely with...
Ophthalmic Azithromycin (AzaSite)
The Medical Letter on Drugs and Therapeutics • Feb 11, 2008 (Issue 1279)
. Roden, M.D., Vanderbilt University School of Medicine
F. Estelle R. Simons, M.D., University ...
The FDA has approved azithromycin 1% ophthalmic solution (AzaSite - Inspire) for treatment of bacterial conjunctivitis in patients > 1 year old. It is formulated, according to the manufacturer, in a controlled-release delivery system that keeps the drug in the eye for several hours.
Spinal Decompression Machines
The Medical Letter on Drugs and Therapeutics • Jun 02, 2008 (Issue 1287)
. Roden, M.D., Vanderbilt University School of Medicine
F. Estelle R. Simons, M.D., University ...
Spinal decompression machines offer a motorized form of mechanical traction. These devices, which are widely advertised to the public as a noninvasive alternative to surgery, are claimed to relieve low back pain by decompressing discs, improving the flow of nutrients into the disc and rehydrating dried-out discs. Devices cleared by the FDA based on substantial similarity to previously approved power traction devices include the Accu- Spina System, DRS System, DRX9000, Lordex Traction Unit, Spinal Health Elite, SpineMED Decompression Table, SpineRx-LDM and VAX-D Therapeutic Table.
Etravirine (Intelence) for HIV Infection
The Medical Letter on Drugs and Therapeutics • Jun 16, 2008 (Issue 1288)
., University Hospital, Copenhagen
Dan M. Roden, M.D., Vanderbilt University School of Medicine
F. Estelle R ...
Etravirine (Intelence - Tibotec), a new non-nucleoside reverse transcriptase inhibitor (NNRTI), has received fast-track FDA approval for use in combination therapy in treatment-experienced adults who have HIV-1 infection resistant to an NNRTI and other antiretroviral agents.
Olopatadine (Patanase) Nasal Spray
The Medical Letter on Drugs and Therapeutics • Jun 30, 2008 (Issue 1289)
. Roden, M.D., Vanderbilt University School of Medicine
F. Estelle R. Simons, M.D., University ...
Olopatadine 0.6% nasal spray (Patanase - Alcon) has been approved by the FDA for treatment of seasonal allergic rhinitis in patients ≥ 12 years old. An H1-antihistamine with mast-cell stabilizing activity, olopatadine is already marketed for treatment of allergic conjunctivitis in a 0.1% solution as Patanol and in a 0.2% solution as Pataday. Azelastine (Astelin), another H1-antihistamine with mast-cell stabilizing activity, has been available for intranasal treatment of allergic rhinitis since 1997.
Intra-Articular Injections for Osteoarthritis of the Knee
The Medical Letter on Drugs and Therapeutics • Mar 27, 2006 (Issue 1231)
knees. Systematic review with meta-analysis. Can Fam
Physician 2004; 50:241.
4. B Arroll and F ...
Now that glucosamine and chondroitin, 2 favorite over-the-counter remedies for painful osteoarthritis (OA) of the knee, have been at least somewhat discredited, some patients will be asking about alternatives. One of these is periodic intra-articular injection of a corticosteroid or hyaluronic acid preparation.
Focalin XR for ADHD
The Medical Letter on Drugs and Therapeutics • Mar 23, 2009 (Issue 1308)
Eric J. Epstein, M.D., Albert Einstein College of Medicine
Sandip K. Mukherjee, M.D. F.A.C.C., Yale ...
Short-acting methylphenidate (MPH) is effective for treatment of attention-deficit/hyperactivity disorder (ADHD), but its 3-5 hour duration of action usually requires mid-day dosing in school, which children may find disruptive or stigmatizing.
Deep Brain Stimulation for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Apr 06, 2009 (Issue 1309)
, M.D. F.A.C.C., Yale School of Medicine
Jordan W. Smoller, M.D., Sc.D., Harvard Medical School ...
Deep brain stimulation (DBS) is increasingly used to treat advanced Parkinson's disease (PD), but few controlled clinical trials have been published. New evidence from a large controlled study has recently become available.